https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-raises-GBP-50-M-EMBARGO-MON-3AM-ET-164529.webp8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:02:412026-08-14 13:56:34NRG raises $67 million for a small molecule for Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Biotech-TV.jpg532959Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:01:482026-09-10 10:24:24Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neil_Miller_CEO_NRG_Therapeutics_-_in_lab.webp9001600Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-09-08 08:00:342026-08-14 14:16:22A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/movers-shakers.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-03-08 08:00:022026-09-10 10:24:02Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-10-31 08:00:162026-08-14 14:24:06NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/alnewstoday_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-09-13 08:00:122026-08-14 14:27:55NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neuroscience_news.webp8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-04-03 08:00:232026-08-14 14:30:329 neuroscience biotech companies you should know about
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/mitochondrial_drug_target_news.webp8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-02-22 08:00:112026-08-14 14:36:14MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s
NRG raises $67 million for a small molecule for Parkinson’s and ALS
c&en
Read more
Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS
Biotech TV
Watch more
A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try
Endpoints News
Read more
Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s
Apple Podcasts
Listen more
Novel Parkinson’s therapy protects mitochondrial function
Drug Discovery World
Read more
NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
Business Weekly
Read more
NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
ALS News Today
Read more
Case Study: Life Sciences – Future50
PwC
Read more
(pdf)
9 neuroscience biotech companies you should know about
Labiotech
Read more
MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s
Bioworld
Read more
Case Study: R&D grant funding
BIA, UK BioIndustry Association
Read more
Parkinson’s disease drug hunters think outside the α-synuclein box
Nature Biotechnology
Read more
(behind paywall)